Trauma therapy
The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic.
1. A method of reducing injury to cells, tissues or organs in a person suffering from hemorrhagic shock as a consequence of trauma comprising:
administering a composition to the person following the trauma, the composition comprising:
(i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and
(ii) a local anaesthetic,
wherein the person is suffering injury to cells, tissues or organs resulting from the hemorrhagic shock as a consequence of the trauma and administering the composition thereby reduces the injury to cells, tissues or organs.
2. The method according to claim 1 , wherein the composition is hypertonic.
3. The method according to claim 2 , wherein the composition includes 7.5% saline.
4. The method according to claim 1 , wherein the composition is administered as one-shot.
5. The method according to claim 1 , wherein the composition is administered directly to the tissue or organ.
6. The method according to claim 1 , wherein component (i) is adenosine.
7. The method according to claim 1 , wherein the local anaesthetic is lignocaine.
8. The method according to claim 6 , wherein the local anaesthetic is lignocaine.
9. The method according to claim 1 , wherein the composition further includes divalent magnesium cations.
10. The method according to claim 9 , wherein the concentration of magnesium cations is up to about 20 mM.
11. The method according to claim 1 , wherein the treatment comprises the further step of subsequently administering to the person a second composition, comprising:
(i) a potassium channel opener or agonist, or an adenosine receptor agonist; and
(ii) a local anaesthetic.
12. The method according to claim 11 , wherein the second composition is administered continuously by infusion.
13. The method of claim 1 , wherein the composition includes an antioxidant.
14. The method of claim 13 , wherein the antioxidant is melatonin.
15. The method of claim 1 , wherein the composition includes an impermeant.
16. The method of claim 15 , wherein the impermeant is insulin.
17. The method according to claim 1 , wherein (i) is adenosine and (ii) is lignocaine.
18. The method according to claim 11 , wherein (i) is adenosine and (ii) is lignocaine.